News | June 19, 2012

CyberKnife Prostate SBRT Data Presented at American Urological Association Meeting

Long-term outcomes for intermediate-risk prostate cancer patients

June 19, 2012 — Accuray Inc. announced that outcome data on intermediate-risk prostate cancer patients treated with CyberKnife Prostate SBRT (stereotactic body radiation therapy) was presented at the 2012 American Urological Association Meeting (AUA) in Atlanta. The prospective monotherapy study, titled, “Four Year Outcomes and Quality of Life Following Stereotactic Body Radiation Therapy: A Rapid, Non-Invasive Alternative for the Treatment of Intermediate-Risk Organ Confined Prostate Cancer,” expands upon prior studies to further evaluate the long-term efficacy and quality of life outcomes from treatment with CyberKnife SBRT for intermediate-risk prostate cancer patients. The study found a 91 percent biochemical control rate at four-years, which is comparable to both surgical and non-surgical treatments for intermediate risk prostate cancer patients, while demonstrating similar to improved toxicity outcomes. 

The study consisted of 81 intermediate-risk organ-confined prostate patients treated by Alan Katz at Winthrop University Hospital with a median follow-up of four years, including 24 patients with a minimum of five years follow-up. This study showcases the long-term published data on the use of the noninvasive CyberKnife SBRT five-day course of treatment for intermediate-risk prostate cancer. Most notably the study found a four-year relapse-free survival rate of 91 percent. Patients experienced mild toxicity with minimal impact on quality of life and immediate to rapid return to normal activity. These results further support the value of CyberKnife prostate SBRT to achieve high rates of long-term disease control while sparing healthy tissue and critical nearby structures, thereby minimizing undesirable side effects typically associated with other treatment modalities and preserving patients' quality of life.

“CyberKnife prostate SBRT offers patients a short five-day, noninvasive treatment for organ-confined prostate cancer,” said Alan Katz, M.D., radiation oncologist at Flushing Radiation Oncology and author of the study. “Based on our study results, patients with intermediate-risk prostate cancer have an option for a less invasive alternative to invasive surgery or six to eight weeks of conventionally fractionated radiation therapy, that effectively and efficiently treats their cancer while preserving their overall quality of life.”

"This study represents positive long-term outcomes of CyberKnife SBRT for intermediate-risk prostate patients, further supporting the value of this patient-centric technique," said Omar Dawood, M.D., M.P.H., senior vice president of global medical affairs for Accuray. “These results add to the rapidly maturing strong foundation of published clinical evidence for CyberKnife prostate SBRT and further support the need to create head-to-head evidence to compare outcomes of this treatment with surgery and conventionally fractionated radiation treatments as is underway in the recently launched PACE study. We look forward to the outcomes of the PACE study, which aims to build upon these results and further support CyberKnife SBRT as a potential gold standard for the treatment for patients with organ-confined prostate cancer.”

For more information: www.accuray.com

Related Content

Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Videos | Radiation Therapy | August 01, 2018
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherap
Videos | AAPM | August 01, 2018
American Association of Physicists in Medicine (AAPM) President Bruce Thomadsen, M.D., professor of medical physics a
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Overlay Init